Get the Stockscreener App
286.08
1.96%
-5.72
After Hours:
286.08
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $286.08, with a volume of 1.24M.
It is down -1.96% in the last 24 hours and down -4.59% over the past month.
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$291.80
Open:
$290.87
24h Volume:
1.24M
Relative Volume:
0.90
Market Cap:
$55.45B
Revenue:
$310.23B
Net Income/Loss:
$1.69B
P/E Ratio:
33.19
EPS:
8.62
Net Cash Flow:
$3.58B
1W Performance:
-1.50%
1M Performance:
-4.59%
6M Performance:
+12.54%
1Y Performance:
+20.26%
1-Day Range:
$281.84
$292.00
1-Week Range:
$281.84
$293.14
52-Week Range:
$218.65
$309.35
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
286.08 | 56.56B | 310.23B | 1.69B | 3.58B | 8.62 |
|
MCK
Mckesson Corporation
|
693.54 | 89.30B | 359.05B | 3.30B | 5.23B | 25.83 |
|
CAH
Cardinal Health Inc
|
155.22 | 37.69B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
67.65 | 8.70B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.699 | 662.04M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
How many analysts rate Cencora Inc. as a “Buy”Post Market Growth Plan With High Returns - jammulinksnews.com
Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo.co
What makes Cencora Inc. stock price move sharplyPrice Action Based Buy Opportunity List Published - metal.it
Fortune 10 Cencora Partners With LOCK'DIN for Nationwide Distribution | LTNC Stock News - Stock Titan
What catalysts could drive Cencora Inc. stock higher in 2025Best Dividend Data Feed Backed By Experts - jammulinksnews.com
Cell and Gene Therapy Third-Party Logistics Market Forecast and Company Analysis Report 2025-2033 Featuring Cencora, Cardinal Health, McKesson, EVERSANA, Knipper Health, Arvato, DHL, and Kuehne+Nagel - GlobeNewswire Inc.
What are analysts’ price targets for Cencora Inc. in the next 12 monthsInvest smarter with actionable trading signals - jammulinksnews.com
What are the latest earnings results for Cencora Inc.Superior trading gains - jammulinksnews.com
How volatile is Cencora Inc. stock compared to the marketCapitalize on market momentum for big wins - jammulinksnews.com
Why Cencora Inc. stock is on top investor watchlistsFree Predictions - metal.it
Cencora (NYSE:COR) shareholders have earned a 25% CAGR over the last five years - Yahoo Finance
What drives Cencora Inc. stock priceDynamic capital growth - PrintWeekIndia
What institutions are buying Cencora Inc. stock nowBreakout stock performance - jammulinksnews.com
What analysts say about Cencora Inc. stockFree Stock Market Query - PrintWeekIndia
How Cencora Inc. stock compares to its top competitorsIs VBTX stock undervalued or overvalued nowRapid wealth multiplication - jammulinksnews.com
Cencora Inc. Stock Analysis and ForecastBreakthrough wealth creation - PrintWeekIndia
How high can Cencora Inc. stock price go in 2025Fastest-growing stock picks - jammulinksnews.com
Will Cencora Inc. stock split in the near futureMarket-crushing stock picks - jammulinksnews.com
Cencora, Inc. (COR): A Bull Case Theory - Insider Monkey
Is Cencora Inc. a good long term investmentExplosive trading opportunities - jammulinksnews.com
Why Cencora Inc. stock attracts strong analyst attentionFree Stock Market Insider Analysis - beatles.ru
Here's What to Expect From Cencora's Next Earnings Report - MSN
Cencora, Inc. shares rise 2.42% after-hours following Citius Oncology's $9.0 million public offering. - AInvest
Cencora Slumps to 447th in Market Rankings as Trading Volume Drops 40.48 Percent - AInvest
Here's Why You Should Add Cencora Stock to Your Portfolio Now - MSN
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.70%
2.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):